Trinity Delta view: Despite significant progress during 2022, including the FDA clearance of Parsortix and the highly positive ovarian cancer data, broader market headwinds dictate a more cautious stance into 2023. These challenging conditions have led to increased focus on cost control at ANGLE’s potential partners and customers, causing delays in commercial uptake. Consequently, revenues are unlikely to accelerate as rapidly as previously anticipated. Regardless of these external factors, ANGL ....
05 Jan 2023
Trinity Delta Lighthouse: ANGLE
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trinity Delta Lighthouse: ANGLE
ANGLE plc (AGL:LON) | 14.0 -0.2 (-9.7%) | Mkt Cap: 36.5m
- Published:
05 Jan 2023 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
2
Trinity Delta view: Despite significant progress during 2022, including the FDA clearance of Parsortix and the highly positive ovarian cancer data, broader market headwinds dictate a more cautious stance into 2023. These challenging conditions have led to increased focus on cost control at ANGLE’s potential partners and customers, causing delays in commercial uptake. Consequently, revenues are unlikely to accelerate as rapidly as previously anticipated. Regardless of these external factors, ANGL ....